Changeflow GovPing Pharma & Drug Safety Dimeric Compounds as Inhibitors of Glycogen Syn...
Routine Guidance Added Final

Dimeric Compounds as Inhibitors of Glycogen Synthase 1 (Gys1)

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office has published patent application EP4587118A1 for dimeric compounds that inhibit Glycogen Synthase 1 (Gys1). The application lists Maze Therapeutics, Inc. as the applicant and details various inventors. This publication relates to potential new therapeutic agents.

What changed

European Patent Office (EPO) publication EP4587118A1 details a new patent application for dimeric compounds designed to inhibit Glycogen Synthase 1 (Gys1). The application, filed by Maze Therapeutics, Inc., outlines methods of use for these compounds, suggesting potential applications in therapeutic areas including metabolic disorders and cancer, as indicated by the IPC classifications.

This is a patent publication, not a regulatory rule or guidance with compliance obligations. Regulated entities in the pharmaceutical sector, such as drug manufacturers and pharmaceutical companies, should note this development as it pertains to potential new intellectual property in the field of drug discovery and development. No immediate compliance actions are required.

Source document (simplified)

← EPO Patent Bulletin

DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF

Publication EP4587118A1 Kind: A1 Mar 18, 2026

Applicants

Maze Therapeutics, Inc.

Inventors

MORGANS JR., David John, MELLEM, Kevin, LEE, Patrick Sang Tae, SINZ, Christopher Joseph, SCHAMMEL, Alexander Wayne, ZIEBENHAUS, Chris, WAHLERS, Jessica, TZITZILONIS, Christos, FASTMAN, Nathan

IPC Classifications

A61P 5/00 20060101AFI20240322BHEP A61P 25/00 20060101ALI20240322BHEP A61P 35/00 20060101ALI20240322BHEP C07D 213/61 20060101ALI20240322BHEP C07D 401/14 20060101ALI20240322BHEP A61K 31/4439 20060101ALI20240322BHEP A61K 31/444 20060101ALI20240322BHEP A61K 47/50 20170101ALI20240322BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4587118A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Discovery
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
GxP
Topics
Drug Discovery Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.